Literature DB >> 15021317

Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.

Mauro Schechter1, Regina F do Lago, Aaron B Mendelsohn, Ronaldo I Moreira, Lawrence H Moulton, Lee H Harrison.   

Abstract

BACKGROUND: Little is known about the behavioral impact, acceptability, and incidence of HIV infection in persons with easy access to post-sexual exposure prophylaxis (PEP) to prevent HIV.
METHODS: Participants were recruited from a well-characterized, high-risk HIV seronegative homosexual male cohort in Rio de Janeiro, Brazil, given a 4-day supply of zidovudine and lamivudine, and instructed to begin PEP immediately after an eligible exposure. For eligible exposures, an additional 24-day supply was provided. Reported behavior, PEP utilization, adverse events, and incident HIV infection were the main study outcomes. The observed and expected incidences of HIV infection were compared.
RESULTS: Two hundred subjects were enrolled and followed for a median of 24.2 months. The median age was 28 years. PEP was initiated 109 times by 68 participants (34.0%). In comparison to reported behavior at baseline, reported high-risk sexual activities on average declined over time for both PEP and non-PEP users. There were no serious drug-related adverse events. There were 11 HIV seroconversions, 10 among non-PEP users and 1 that was a PEP failure. The overall seroincidence was 2.9 per 100 person-years (95% CI = 1.4, 5.1). The expected number of new HIV infections and corresponding expected seroincidence based on the risk profile were 11.8 and 3.1, respectively (P > 0.97). The most commonly reported reasons for not initiating PEP among seroconverters were sex with a steady partner and not considering the exposure to be of sufficiently high risk to warrant PEP.
CONCLUSION: PEP was safe and did not appear to be associated with increases in reported high-risk behavior in our cohort. Ready access to PEP did not appear to substantially affect HIV transmission, suggesting a limited public health impact of this intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15021317     DOI: 10.1097/00126334-200404150-00010

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  65 in total

1.  Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston community health center: 1997-2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2015-01       Impact factor: 5.078

2.  Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men.

Authors:  Sarit A Golub; William Kowalczyk; Corina L Weinberger; Jeffrey T Parsons
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

3.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

Review 4.  Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.

Authors:  Douglas Krakower; Kenneth H Mayer
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

5.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

Review 6.  Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies.

Authors:  Lisa A Eaton; Seth Kalichman
Journal:  Curr HIV/AIDS Rep       Date:  2007-12       Impact factor: 5.071

7.  HIV medical providers' perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas.

Authors:  Allan E Rodríguez; Amanda D Castel; Carrigan L Parish; Sarah Willis; Daniel J Feaster; Michael Kharfen; Gabriel A Cardenas; Kira Villamizar; Michael Kolber; Liliana Vázquez-Rivera; Lisa R Metsch
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

Review 8.  Preparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxis.

Authors:  Stephanie E Cohen; Albert Y Liu; Kyle T Bernstein; Susan Philip
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

9.  Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education.

Authors:  Matthew J Mimiaga; Patricia Case; Carey V Johnson; Steven A Safren; Kenneth H Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

Review 10.  HIV prevalence among female sex workers, drug users and men who have sex with men in Brazil: a systematic review and meta-analysis.

Authors:  Monica Malta; Monica M F Magnanini; Maeve B Mello; Ana Roberta P Pascom; Yohana Linhares; Francisco I Bastos
Journal:  BMC Public Health       Date:  2010-06-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.